NovaDigm Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Grand Forks ND United States (2005)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2011
NCT01273922
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

NovaDigm Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ndv-3 (4 trials)

Drugs in Phase 1 Trials (1)

potassium alum (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 2)

Candidiasis, Vulvovaginal (Phase 2)

Communicable Diseases (Phase 1)

Infections (Phase 1)

Staphylococcal Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2